Date: 2026-04-02 Analyst: Bert Hochfeld Market cap: ~2.6B|Shareprice: 28.50 (est. Apr 2, 2026) | Shares: 90.9M FY ends: December (calendar year) Atlas baseline: Read and incorporated. I agree with the qualification gate, six-factor scoring, and scuttlebutt findings. My analysis adds explicit valuation discipline using EV/S cohort methodology, convertible debt term analysis, and GARP-spectrum positioning. I diverge from Atlas on the weight given to FSGS binary risk in position sizing.
Summary: I have not covered Travere Therapeutics in the newsletter, but applying my framework, TVTX presents one of the most compelling risk-reward profiles I have seen in commercial-stage biotech. FILSPARI, the company's first-in-class kidney drug, grew revenue 144% YoY to $322M in FY25 with 98% gross margins and brought the company to its first year of positive operating cash flow. The stock trades at a P/S of 5.3X on 490.7Moftrailingrevenue, whichtranslatestoaPEGof0.05X—anumbersolowitmakesthemostdiscountedsoftwarenamesIfollowlookexpensivebycomparison.TheFSGSPDUFAdecisiononApril13is11daysawayandrepresentsanasymmetriccatalyst : approvalwouldmakeFILSPARIthefirstandonlydrugapprovedforFSGS, roughlydoublingtheaddressablepatientpopulationwithnoincrementalfieldforceinvestment.Theconvertiblenotes(275M face, $31.87 conversion price, maturing March 2029) are currently out-of-the-money and redeemable by the company since March 2026. This is a GARP opportunity of the first order, tempered only by the binary nature of the FSGS decision and the transition from single-drug concentration to multi-product platform.
Travere Therapeutics is a specialty pharmaceutical company focused on rare kidney and metabolic diseases. The business has two commercial products:
FILSPARI (sparsentan) is a once-daily oral dual endothelin and angiotensin receptor antagonist, approved for IgA nephropathy (IgAN) in February 2023. It is the only IgAN therapy with both proven eGFR benefit vs. active comparator and KDIGO first-line guideline endorsement (September 2025). FY25 FILSPARI net sales were $322M, representing 65.6% of total revenue. The REMS program was simplified in August 2025 from monthly to quarterly monitoring, meaningfully reducing prescriber friction.
Tiopronin (Thiola/Thiola EC) is a legacy cystinuria treatment generating approximately $88.5M annually, stable and slowly declining as FILSPARI becomes the dominant revenue driver.
The company also generates license and collaboration revenue, primarily from CSL Vifor (ex-US sparsentan rights) and Chugai (Japan). FY25 license revenue was $80.3M, inflated by CSL Vifor milestone payments in Q2-Q3 that will not recur at the same magnitude.
What differentiates Travere is the platform approach in nephrology: IgAN (commercial), FSGS (PDUFA April 13), post-transplant IgAN/FSGS (SPARX Phase 2/3), and classical homocystinuria (pegtibatinase, Phase 3 HARMONY restarted Q1 2026). The existing field force of 100+ nephrology reps creates leverage for any additional kidney-targeted approval.
Headline KPIs (FY25):
The revenue story is straightforward: FILSPARI is in a classic drug-launch S-curve. I find the quarterly progression instructive.
| Quarter | FILSPARI ($M) | QoQ % | YoY % | Total Rev ($M) | YoY % |
|---|---|---|---|---|---|
| Q1 FY24 | 19.8 | — | — | 41.4 | 34.0% |
| Q2 FY24 | 27.1 | +37% | — | 54.1 | 68.0% |
| Q3 FY24 | 35.6 | +31% | — | 62.9 | 69.5% |
| Q4 FY24 | 49.6 | +39% | — | 74.8 | 65.9% |
| Q1 FY25 | 55.9 | +13% | +182% | 81.7 | 97.3% |
| Q2 FY25 | 71.9 | +29% | +165% | 114.4 | 111.5% |
| Q3 FY25 | 90.9 | +26% | +155% | 164.9 | 162.2% |
| Q4 FY25 | 103.3 | +14% | +108% | 129.7 | 73.4% |
The Q4 FY25 total revenue decline ($129.7M vs. 164.9MQ3)isentirelyafunctionoflumpylicenserevenue(3.1M Q4 vs. $51.7M Q3 CSL Vifor milestone). Net product sales actually grew from $113.2M to $126.6M sequentially (+11.8%). This is a critical distinction: the underlying product franchise is not decelerating.
The Q4 PSF count of 908 (all-time high, up 24% from 731 in Q3) is the most important forward-looking number in the entire report. PSFs are a leading indicator of revenue — prescriptions in the pipeline that have not yet converted to filled scripts. This signals robust demand momentum entering FY26.
The operating leverage story is remarkable. GAAP operating margins progressed from -336% in Q1 FY24 to -25% in Q4 FY25. Non-GAAP operating margins hit +31.5% in Q3 FY25 (a $52M license quarter, to be fair) and settled at -2.2% in Q4 when license revenue normalized. For the full year, Non-GAAP operating income was $42.8M on $490.7M revenue — an 8.7% margin, a swing of $286M from FY24's negative $243.4M.
Annual OCF went from -325.4M(FY23)to−230.0M (FY24) to +37.8M(FY25).Thecompanyisself − fundingforthefirsttime.FCFremainsnegative(−20.4M) due to $58.2M in capitalized intangible and royalty investments, but the underlying product business generates cash.
I want to be specific about this because it matters. FY25 SG&A was $337.2M, up 28% from $264.1M in FY24. That is faster than net product revenue growth of 81%. Q4 FY25 SG&A was $101.7M — up 46% YoY — reflecting pre-launch investment for FSGS. This is the critical watch item: if FSGS is approved, the incremental SG&A is already in the run-rate and the operating leverage is immediate. If FSGS is rejected, $100M+/quarter of SG&A needs to be rationalized against IgAN-only revenue. The beer does not get any colder if you are carrying $400M of annual SG&A against a $410M product revenue base without a second indication.
The IgAN market has gone from zero approved disease-modifying therapies to four in under three years. This is the early innings of a therapeutic category, analogous to the early immune-oncology wave where the total addressable market expanded faster than any single drug lost share.
FILSPARI's moat:
Competitive threats:
The IgAN market is estimated at ~$878M globally in 2025, growing at a 30% CAGR. With FILSPARI generating $322M domestically and CSL Vifor commercializing ex-US, Travere has roughly 44% share of a market that is expanding by $200M+ per year. I expect FILSPARI's absolute revenue to continue growing even as market share compresses from 44% toward 30-35% by FY28, because the denominator is growing so rapidly.
The FILSPARI sNDA for FSGS has a PDUFA target date of April 13, 2026 — 11 days from this analysis. This is the single most important catalyst for the stock.
What happened: FDA accepted the sNDA based on DUPLEX (Phase 3) and DUET (Phase 2) data showing significant proteinuria reduction vs. irbesartan. The original PDUFA was January 13, 2026, but FDA extended it by 3 months for a "Major Amendment" — the company submitted additional information to characterize clinical benefit. Notably, the FDA removed the planned Advisory Committee meeting — this is generally interpreted as a positive signal, as AdComs are typically convened when the FDA needs external input on a close decision.
If approved: FILSPARI becomes the first and only approved drug for FSGS. The addressable population is approximately 30,000-50,000 patients, comparable to the IgAN population. The same field force, same payer infrastructure, same nephrology relationships — this is a pure operating leverage event. Implied FY26 FILSPARI revenue with FSGS ramp: $450-500M+. FY26 total revenue could reach $600-800M.
If rejected: Travere remains a strong IgAN franchise with $400M+ annual product revenue. The stock likely declines 30-40% as the market removes the FSGS premium, but the IgAN-only valuation floor is $1.8-2.2B based on $410M product revenue at 4.5-5.5X P/S.
My assessment: I am not a clinical pharmacologist, and I will not pretend to assign precise probability to FDA decisions. The AdCom removal, the 3-month extension (which allowed the company to submit supplementary data rather than requiring a new trial), and the existing clinical data package (statistically significant proteinuria reduction in both studies) are constructive signals. But the "Major Amendment" characterization and mixed DUPLEX efficacy results introduce genuine uncertainty. This is a binary event that investors should size accordingly.
The scout brief flagged $311.7M in convertible notes without full terms. My supplementary research provides the critical details:
At the current stock price of ~28.50, theconversionisout − of − the − money(31.87 is 12% above current). If FSGS is approved and the stock trades to $35-40, the converts become in-the-money. Full conversion would add ~8.6M shares (9.5% dilution on 90.9M base). However, with the company now able to redeem and near cash flow positive, management may choose to repay rather than dilute. The $322.8M in cash and securities technically covers the $275M face value if management prioritizes debt elimination over maintaining a cash cushion.
The balance sheet carrying value of $311.7M vs. $275M face value reflects ASC 815 accounting treatment (accreted discount). The economic liability is the $275M face value.
I want to be specific about these:
FSGS rejection (April 13). Binary event. If rejected, the stock likely drops to $18-22 (IgAN-only valuation). The pre-FSGS SG&A investment (~$100M/quarter) would need to be right-sized. This is the concentration limit question — position sizing must account for this outcome.
IgAN competitive share erosion. Vanrafia's no-REMS advantage is genuine for prescriber convenience, even though FILSPARI has the stronger clinical profile. Market share compression from 44% toward 30-35% over 3 years is realistic even as the total market grows.
GTN headwind. Management guided mid-20% gross-to-net for FY26 vs. ~20% in FY25. On a 400M + FILSPARIgrosssalesbase, 500bpsofGTNexpansionis 20-25M of net revenue drag. This partially offsets volume growth and is a structural headwind as payer mix shifts toward Medicaid.
Single product concentration. FILSPARI is 65.6% of FY25 revenue and 100% of the growth. Tiopronin is stable-to-declining. Until pegtibatinase (HARMONY, Phase 3) or another indication advances, this remains a one-product story.
A/R expansion bears monitoring. Q4 FY25 accounts receivable was $80.1M, up 195% YoY on 73% revenue growth. The 2.7X ratio of A/R growth to revenue growth suggests either longer collection cycles or payer mix shifts. This is not alarming for a rapidly scaling pharma product, but if A/R continues to outpace revenue, it warrants scrutiny for cash collection quality.
Here is where I apply the framework rigorously.
| Metric | TVTX | Cohort Reference |
|---|---|---|
| Market cap | ~$2.6B | — |
| Net cash | +$11.1M | — |
| EV (approx.) | ~$2.6B | — |
| TTM Revenue | $490.7M | — |
| EV/S (TTM) | 5.3X | Mid-cap biotech (20-40% growth): 4-6X |
| EV/S (FY26E ~$600M) | 4.3X | — |
| Revenue YoY | 110.3% | Cohort avg for 110%+ growth: 12-20X EV/S |
TVTX trades at 5.3X trailing EV/S while growing revenue 110% YoY. For context, in the software universe I follow, companies growing at 30-50% trade at 7-14X EV/S. Companies growing at >50% trade at 12-20X. TVTX is growing more than twice as fast as a 50% grower and trades at less than half the multiple. The discount to the >50% growth cohort is approximately 60-70% — a level of disconnection I rarely see outside of bankruptcy risk or fraud allegations.
Now, I must caveat: biotech deserves a structural discount to software because revenue quality differs. Drug revenue is product-based (not recurring/subscription), faces patent expiry, regulatory risk, and competitive substitution in ways that cloud software generally does not. A 30-40% discount to software multiples is reasonable as a biotech-specific adjustment. Even applying that discount, TVTX should trade at 8-12X EV/S for this growth profile — 50-100% above the current level.
| Metric | Value |
|---|---|
| EV/S | 5.3X |
| Revenue growth (YoY) | 110.3% |
| PEG (EV/S / growth %) | 0.05X |
A PEG of 0.05X is the lowest I have encountered in any company I have analyzed. For reference, my threshold for "exceptional value" is PEG < 0.5X. AppLovin, which I highlighted as exceptionally cheap in February 2026 at a PEG below 0.5X, traded at 10X the PEG ratio of TVTX. This is either the market pricing in a very high probability of catastrophic downside (FSGS rejection + competitive destruction) or a significant mispricing.
| Metric | Value |
|---|---|
| Non-GAAP NI (FY25) | $81.1M |
| Non-GAAP EPS (FY25) | $0.91 |
| P/E (Non-GAAP, trailing) | ~32X |
| Est. FY26 Non-GAAP EPS (base) | $1.50-2.00 |
| Forward P/E (FY26E) | ~15-19X |
A forward P/E of 15-19X for a company growing revenue 50-70%+ (FY26 estimate with FSGS approval) would be, to use the precise language, extraordinary. For a company growing at even 30%, a 15-19X forward P/E implies a PEG well below 1.0X — which is my threshold for strong buy in profitable or near-profitable companies.
FY25: 110.3% revenue growth + 7.7% OCF margin = 117%. This is in the top 1% of all companies I track. Rule of 40 scores above 60 are exceptional; above 100 is essentially unheard of outside of the hypergrowth phase. The Rule of 40 will compress as revenue growth decelerates, but even at 40% FILSPARI growth + 15% OCF margin in FY27, the score would be ~55 — still firmly in quality territory.
The risk-reward here is asymmetric in the investor's favor. The bull case offers 60-100% upside if FSGS is approved and the company executes on the expanded indication. The base case offers 25-45% upside with moderate execution. The bear case — FSGS rejection — results in 25-35% downside, but the IgAN franchise alone is a $400M+ revenue business growing mid-20s% with 98% gross margins and positive operating cash flow. That is not a broken business; that is a business the market has paid 5X revenue for even without FSGS.
The PEG of 0.05X, Rule of 40 of 117%, and the inflection from chronic cash burner to OCF-positive are the quantitative foundation. The FSGS approval, KDIGO first-line endorsement, REMS simplification, and record PSF count are the qualitative catalysts.
My concern — and it is a genuine one — is position sizing around a binary event. I would not take a full position ahead of the April 13 PDUFA. A 2-3% allocation in a high growth portfolio, with a plan to add to 5-6% on FSGS approval, is the disciplined approach. The concentration limit applies regardless of how compelling the numbers are, and binary regulatory events are the one thing that cannot be analyzed away with financial data.
Rating: Buy (initiate 2-3% position, add on FSGS approval)
I am a numbers guy, and these numbers are exceptional. The question is whether the April 13 outcome validates the platform thesis or confines the company to a single-indication franchise. Either way, the current valuation underprices the existing business. A relative bargain, with a catalyst 11 days away.
First coverage. No prior position. Data from scout brief 2026-04-01. Market cap estimated at ~2.6Bbasedon 28.50 share price x 90.9M shares outstanding. Convertible note terms from GlobeNewswire (March 2022 offering). Competitive intelligence from Fierce Pharma, HCPLive, DelveInsight.